Compare Cintas Corporation (CTAS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Gilead Sciences, Inc. — how do they compare? Cintas Corporation trades at $205.28 (market cap $82.15B), while Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 2× Cintas Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| CTAS | GILD | |
|---|---|---|
Market Cap | $82.15B | $168.35B |
Sector | Industrials | Health |
52-Week High | $225.10 | $155.80 |
52-Week Low | $163.55 | $110.56 |
Enterprise Value | $84.56B | $191.42B |
Dividend Yield | 1.01% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
